Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Non-Small Cell Lung Cancer ALK-positive 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1ALK Positive Non-small Cell Lung Cancer 1

Interventions

Specimen Handling 37Carboplatin 30Magnetic Resonance Spectroscopy 29pembrolizumab 28Pemetrexed 28Cisplatin 24Paclitaxel 16Nivolumab 13Docetaxel 13durvalumab 12Gemcitabine 12osimertinib 11Immunoglobulin G 8Etoposide 8Disulfides 8130-nm albumin-bound paclitaxel 8atezolizumab 7Taxes 7Biopsy 7Ramucirumab 6Radiotherapy 6Radiosurgery 6Radiation 6Platinum 6Cetuximab 6X-Rays 5Irinotecan 51,2-diaminocyclohexaneplatinum II citrate 5Observation 4Ipilimumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × lorlatinib × 30 days × Clear all
NCT07567352 2026-05-12

A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment

Pfizer

Active not recruiting
200 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡